Paper39504356
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.
Ding J and 31 others. Sci Transl Med, 2024. Cited by 44 papers, by iCite.
Cite this record
ConductScience Library. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population. Papers, record 39504356. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39504356
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| China | |
| Liver | |
| Liver Cirrhosis | |
| Liver Neoplasms | |
| Metabolomics | |
| Proteomics | |
| Signal Transduction | |
| East Asian People |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 DK134549 | NIDDK NIH HHS | United States | R01DK134549 | PubMed |
Source NIH RePORTER
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 44 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953027 | Omics-derived signatures in metabolic dysfunction-associated steatotic liver disease: from molecular characterization to clinical translation. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42953027 | PubMed |
| 42866058 | Omics-based Decoding of Metabolic Dysfunction-associated Fatty Liver Disease: From Pathogenesis to Clinical Translation. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/42866058 | PubMed |
| 42823416 | Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression. | Nat Commun | 2026 | https://conductscience.org/library/papers/42823416 | PubMed |
| 42793749 | An Attention-Residual Hybrid CNN for CT-Based Multiclass Classification of Alcohol-Related Liver Disease: Differential Diagnosis Against HBV-Related Cirrhosis. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42793749 | PubMed |
| 42687025 | Molecular mechanisms and pathogenesis of MASH. | Nature | 2026 | https://conductscience.org/library/papers/42687025 | PubMed |
| 42687024 | Current therapeutic landscape and future treatment perspectives of MASH. | Nature | 2026 | https://conductscience.org/library/papers/42687024 | PubMed |
| 42627788 | Integrated liver transcriptomic data reveal differences in aging-associated regulation between metabolic dysfunction-associated steatotic liver disease and normal liver aging. | PLoS One | 2026 | https://conductscience.org/library/papers/42627788 | PubMed |
| 42396665 | Oral‑gut axis in systemic disease: A barrier‑metabolism‑immunity three‑dimensional regulatory model (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42396665 | PubMed |
| 42317344 | Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42317344 | PubMed |
| 42245952 | The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42245952 | PubMed |
| 42191458 | EASL position paper on preclinical models of steatotic liver disease. | J Hepatol | 2026 | https://conductscience.org/library/papers/42191458 | PubMed |
| 42189413 | Clinical clustering identifies MASLD subtypes with distinct longitudinal cardiovascular risks and lipidomic profiles. | Hepatol Int | 2026 | https://conductscience.org/library/papers/42189413 | PubMed |
| 42057080 | Metabolomic signatures of hepatic steatosis reveal heterogeneity in cardiometabolic risk and responses to lifestyle interventions in type 2 diabetes: a post hoc analysis. | Cardiovasc Diabetol | 2026 | https://conductscience.org/library/papers/42057080 | PubMed |
| 42036225 | [Precise clinical classification of metabolic associated fatty liver disease]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42036225 | PubMed |
| 42021999 | Identification of novel therapeutic targets for liver fibrosis, cirrhosis, and hepatocellular carcinoma via dual-omics analysis and preliminary exploration of regulatory mechanisms. | Clin Exp Hepatol | 2025 | https://conductscience.org/library/papers/42021999 | PubMed |
| 41930175 | Comprehensive Bioinformatics Analysis and Experimental Verification RNF186 Is a Recurrence Signature Gene of Hepatocellular Carcinoma that Promotes Cell Proliferation. | Oncol Res | 2026 | https://conductscience.org/library/papers/41930175 | PubMed |
| 41928880 | Lipid metabolism-MAFLD crosstalk: mechanisms and therapy. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41928880 | PubMed |
| 41926040 | Targeting the Gut-Liver Mitochondria Axis in MASLD: Mechanisms and Therapeutic Perspectives. | Curr Med Sci | 2026 | https://conductscience.org/library/papers/41926040 | PubMed |
| 41851447 | Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41851447 | PubMed |
| 41826328 | Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD. | Nat Commun | 2026 | https://conductscience.org/library/papers/41826328 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39504356
GET https://conductscience.org/api/papers/v1/39504356/authors?page=2